Protagenic Therapeutics I...
(PTIX)
undefined
undefined%
At close: undefined
0.53
-3.10%
After-hours Jan 08, 2025, 06:56 PM EST
Company Description
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
The company is based in New York, New York.
Protagenic Therapeutics Inc.
| Country | United States |
| IPO Date | Apr 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Dr. Garo H. Armen Ph.D. |
Contact Details
Address: 149 Fifth Avenue New York, New York United States | |
| Website | https://www.protagenic.com |
Stock Details
| Ticker Symbol | PTIX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001022899 |
| CUSIP Number | 74365N103 |
| ISIN Number | US74365N2027 |
| Employer ID | 06-1390025 |
| SIC Code | 7389 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexander Kenneth Arrow C.F.A., M.D. | Chief Financial Officer & Secretary |
| Dr. Andrew Slee Ph.D. | Chief Operating Officer |
| Dr. Garo H. Armen Ph.D. | Co-Founder & Executive Chairman of the Board |
| Dr. Robert Benjamin Stein M.D., Ph.D. | Chief Medical Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 07, 2025 | S-3/A | [Amend] Filing |
| Jan 06, 2025 | DEFA14A | Filing |
| Jan 03, 2025 | DEF 14A | Filing |
| Dec 27, 2024 | 424B3 | Filing |
| Dec 20, 2024 | S-1 | Filing |
| Dec 19, 2024 | PRE 14A | Filing |
| Dec 03, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | 10-Q | Quarterly Report |